AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05728177 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Inhalation Aromatherapy
Description: Aromatherapy is safe, well prepared mixture used in the study that prepared by professor of pharmacology, faculty of pharmacy by mixing lavender essential oil and lavender hydrolate~Patients' medical charts in the outpatient clinic were reviewed to identify those who meet the inclusion criteria. Patients who meet the predetermined inclusion criteria were recruited in the study using simple randomization technique using computer-generated sequence technique to pick up these patients. After simple sampling and dividing patients into two groups of study and control. Patients from the study and control groups were interviewed individually by the researcher to apply the study tools as a pretest. Aromatherapy intervention was carried out for patients in the study group while those in the control group were left without any intervention to undergo the usual outpatient routine care.
Study NCT04771598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise with the phone application
Description: 1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home.
Study NCT04771598 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breathing exercise
Description: 1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week
Study NCT06129604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1495
Description: Eligible subjects will receive study treatment of 50mg TPST-1495 taken orally, once a day for 7 days prior and discontinued 3 days prior to scheduled surgery.
Study NCT05901935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c injection, 3.0 mg/kg, Q3W.
Study NCT05901935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: IV, 6 mg/kg, D1, Q3W
Study NCT05901935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: IV, 25 mg/m\^2，D1、D8，Q3W
Study NCT05901935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine tablets
Description: PO 1000 mg/m\^2, bid, D1-D14, Q3W
Study NCT05472129 — intervention group
Intervention type: OTHER
Intervention: self-administered questionnaires
Description: The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained
Study NCT06400849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy alone of the upper or lower limbs
Description: Self-controlled trial with only standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
Study NCT06400849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy and crompression of the upper or lower limbs
Description: Self-controlled trial adding compression to standard cryotherapy. Compression glove and foot sock will only be worn on one hand and one leg on the same side allocated by randomisation
Study NCT05610501 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound guided tru-cut biopsy
Description: Tru-cut biopsies can collect tissue specimens via a needle of 18G A tru-cut biopsy can be performed under the guidance of different imaging modalities including ultrasound
Study NCT05163496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (Usona Institute)
Description: PAP + psilocybin 25 mg
Study NCT05163496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active placebo
Description: PAP + niacin 250mg
Study NCT04431258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABTL0812
Description: ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
Study NCT04431258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.
Study NCT04431258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
Study NCT06534619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 minutes.
Study NCT06534619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rocabado exercises
Description: 6 Rocabado exercises 6 Reps each.
Study NCT06534619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maitland oscillatory mobilizations
Description: Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are anterior, lateral and inferior glides
Study NCT04894422 — intervention group
Intervention type: OTHER
Intervention: Observational intervention
Description: Voluntarily (not) wearing a face mask (cotton or surgical) for 4 hours, following the government's guidelines during the COVID-19 pandemic.
Study NCT05198128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium intravenous infsuion
Description: intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes
Study NCT05198128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % saline
Description: 0.9 % saline
Study NCT06496490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: HER2 dual-antibody-drug Conjugate (ADC).
Study NCT06496490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection combined with Benmelstobart injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
Study NCT05890599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments.~Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume.
Study NCT05890599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education courses are conducted on-site once a week for 90 minutes over 12 weeks by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.
Study NCT05940532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugemalimab and Chemotherapy
Description: Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years.
Study NCT05418699 — intervention group
Intervention type: DEVICE
Intervention: closed-loop insulin pump
Description: Follow up of patients with real-time closed-loop insulin delivery systems
Study NCT06350032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preservative-free parenteral treprostinil
Description: Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.
Study NCT04749030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Faecal microbiota transplantation (FMT) capsules
Description: The faeces is minimally processed through a series of centrifugation steps and dispensed into double-coated, acid resistant enterocapsules. A single treatment includes approximately 22 capsules (\~50 grams of original donor faeces).
Study NCT04749030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo capsules are produced from a suspension of 50% glycerol, 40% sterile saline and 10% food coloring in enterocapusles
Study NCT06305949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimized transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation 2mA for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
Study NCT06305949 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation
Description: transcranial Direct Current sham Stimulation for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
Study NCT05156190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bright classrooms with light level over 1000 lux
Description: Grade 2 primary school students at the intervention groups will study in bright classrooms for three years and incidence of myopia will be compared with those in conventional classrooms
Study NCT05845138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 for injection ; capecitabine
Description: SHR-A1811 for injection; Capecitabine tablets
Study NCT05684081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital payment
Description: The proposed intervention is designed to support the implementation of polio campaigns through digital payments
Study NCT06336668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk-based HMF
Description: The study subject will be fed human milk fortified with a human-milk-based HMF.
Study NCT06336668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk-based HMF
Description: The study subject will be fed human milk fortified with a human-milk-based HMF.
Study NCT05485805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and caffeine (BAY2880376)
Description: Tablet, oral use, single dose
Study NCT05485805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (Aleve)
Description: Tablet, oral use, single dose
Study NCT05485805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Tablet, oral use, single dose
Study NCT05485805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral use, single dose
Study NCT04820855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: This is the treatment program devised win conjunction with a pelvic floor physical therapist. It is a daily yoga series and mindfulness with a Smartphone app.
Study NCT04820855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Cares
Description: This is standard treatment for Interstitial cystitis with your provider.
Study NCT04820855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Cares
Description: This is standard treatment for Interstitial cystitis with your provider.
Study NCT06241248 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid sepsis diagnostic test
Description: The different stages of the OCEAN Dx whole blood bacterial identification test. Identification is carried out using 9 ml of whole blood taken at the patient's bedside, and is provided after comparing the DNA sequence of the bacteria with a database. The rapid sepsis diagnostic test developed by OCEAN Dx can identify the bacteria responsible for the infection in just 4 hours at present, and soon in 3 hours. Subject to future innovations, it will probably even be possible to obtain a positive result for the presence of bacteria in the patient's sample in just 2 hours.
Study NCT06053476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
Study NCT06053476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Description: After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
Study NCT06053476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-shot paravertebral block
Description: At the beginning of surgery, before pleurectomy, a single shot PVB will be placed at 10 levels (T2-T11) by the surgeon with Ropivacaine 7.5mg/mL and 2-3mL per site under direct thoracoscopic vision. The injection site will be chosen at the paravertebral space, just lateral adjacent to the sympathetic trunk.
Study NCT05736016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)
Description: All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
Study NCT05736016 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)
Description: All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
Study NCT04675086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1-proteinase inhibitor
Description: Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
Study NCT06503796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 4mg/kg/d, oral
Study NCT06503796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: Use only in children who remain positive for HBV-DNA and/or HBsAg after 1 year of age. Regular interferon (3 million U/m2 body surface area, intramuscular or subcutaneous, every other day, adjusted during treatment according to the child's specific tolerance) for 52 weeks.
Study NCT06437132 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: The study is observational and will not include any specific interventions other than the regular care practice that the participants receive from their care providers. The study will use a wrist-mounted smartwatch for monitoring (Garmin VivoActive5). Previous studies show acceptability toward wearable devices among persons with dementia. Moreover, the investigator will use Somnofy, VitalThings, a radar installation mounted behind the patients bed. At the very end of life, the investigator will also apply Shimmer3 Ebio sensor measuring the patients breathing activities. Before starting the data collection, care staff will recognize any discomfort or distress potentially caused by the devices, in which case the relevant device will be immediately removed.
Study NCT05296512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
Study NCT05296512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib.
Study NCT06053476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late chest tube removal
Description: Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system
Study NCT06053476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late chest tube removal
Description: Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be left in place during a fixed period of 3 postoperative days. The chest tube will be removed at the earliest at POD 3 in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of bloody drainage by the Thopaz+ system
Study NCT04675086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiviral Agents
Description: a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
Study NCT04675086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral Agents
Description: a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
Study NCT06053476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early chest tube removal
Description: Postoperatively, the chest tube is connected to a Thopaz+ system (Medela inc.) and installed to -2 or -5 cm H2O.~The chest tube will be removed at the earliest at 4 hours postoperatively in case the following criteria are met:~1. The patient is lucid and capable of sitting up straight in bed on his/her own~2. No air leakage indicated by the Thopaz+ system during at least 4 hours, or \<15 mL/min air leakage during at least 6 hours~3. Postoperative X ray (performed at least 4 hours after surgery or ultimately performed the morning of POD1) demonstrating complete lung expansion at the level of the hilum.~4. Absence of pure blood drainage by the Thopaz+ system
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07852352 Influenza saRNA 1
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836391 Influenza saRNA
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836394 Influenza saRNA
Description: Intramuscular injection